Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C

Hepatology Research

Volumn 46, Issue 3, 2016, Pages E174-E180

  Ikezaki, Hiroaki ^a,b   Nomura, Hideyuki ^c   Furusyo, Norihiro ^a,b   Ogawa, Eiichi ^a,b   Kajiwara, Eiji ^d   Takahashi, Kazuhiro ^e   Kawano, Akira ^f   Maruyama, Toshihiro ^f   Tanabe, Yuichi ^g   Satoh, Takeaki ^h   Nakamuta, Makoto ⁱ   Kotoh, Kazuhiro ^b   Azuma, Koichi ^j   Dohmen, Kazufumi ^k   Shimoda, Shinji ^b   Hayashi, Jun ^l  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c Shin Kokura Hospital   (Japan)

^d STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^e HAMANOMACHI HOSPITAL   (Japan)

^f KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^g Fukuoka City Hospital   (Japan)

^h Kokura Medical Center   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION   (Japan)

^j Department of Medicine   (Japan)

^k CHIHAYA HOSPITAL   (Japan)

^l Haradoi Hospital   (Japan)

more..

Author keywords

Advanced fibrosis; Antitumor; Beta interferon; Hepatocellular carcinoma

Indexed keywords

BETA INTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHRONIC HEPATITIS C; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; JAPANESE (PEOPLE); LIVER CELL CARCINOMA; LIVER FIBROSIS; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SUSTAINED VIROLOGICAL RESPONSE;

EID: 84940676581     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12555     Document Type: Article

References (31)

1. Darrick LK, Raymond CT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer 2015 (Epub ahead of print). doi: 10.1002/cncr.29528
2. Kanwal F, Hoang T, Kramer JR et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140: 1182-8.
3. AASLD. Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: http://www.hcvguidelines.org. Accessed April 4, 2015.
4. European Association for Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420. doi:
5. Karino Y, Toyota J, Ikeda K et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013; 58: 646-54.
6. Miura M, Maekawa S, Sato M et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res 2014; 44: E360-E367.
7. Ogawa E, Furusyo N, Kajiwara E et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study. J Hepatol 2013; 58: 495-501.
8. Hiramatsu N, Oze T, Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res 2015; 45: 152-61.
9. Takeyasu M, Akuta N, Suzuki F et al. Long-term interferon monotherapy deduces the risk of HCV-associated hepatocellular carcinoma. J Med Virol 2012; 84: 1199-207.
10. Ikezaki H, Furusyo N, Ogawa E et al. Efficacy and tolerance of interferon beta plus ribavirin treatment for chronic hepatitis C patients with depression or thrombocytopenia comparison with pegylated interferon alpha plus ribavirin treatment. J Liver 2014; 3: 155.
11. Nomura H, Miyagi Y, Tanimoto H, Yamashita N. Interferon-beta plus ribavirin therapy can be safely and effectively administered to elderly patients with chronic hepatitis C. J Infect Chemother 2014; 20: 489-92.
12. Arase Y, Suzuki Y, Suzuki F et al. Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients. Intern Med 2011; 50: 2083-8.
13. Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J. A comparison of the antitumor effects on interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine 2006; 33: 121-8.
14. Yamaji K, Nabeshima S, Murata M et al. Interferon-alpha/beta upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcninoma cell lines and in chronic hepatitis C patients during interferon-alpha/beta treatment. Cancer Immunol Immunother 2006; 55: 394-403.
15. Kashiwagi K, Furusyo N, Kubo N et al. A prospective comparison of the effect on interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence on hepatocellular carcinoma development. J Infect Chemother 2003; 9: 333-40.
16. Kumada H, Okanoue T, Onji M et al. Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis. Ministry of Health, Labor and Welfare of Japan. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40: 8-13.
17. Bruix J, Sherman M, Llovet JM et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for Study of the Liver. J Hepatol 2001; 35: 412-30.
18. Colucci G, Ferguson J, Harkleroad C et al. Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study. J Clin Microbiol 2007; 45: 3595-600.
19. Ahmed WH, Furusyo N, Zaky S et al. Pretreatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients. World J Gastroenterol 2013; 19: 1387-95.
20. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
21. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009; 83: 127-34.
22. European Association of the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 2012; 32 (Suppl 1): S2-8.
23. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
24. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
25. Kutala KB, Geudj J, Asselah T et al. Impact of treatment against Hepatitis C virus on the overall survival in naïve patients with advanced liver disease. Antimicrob Agents Chemother 2015; 59: 803-10.
26. Shimada M, Takenaka K, Gion T et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996; 111: 720-6.
27. Shimomura S, Nishiguchi S. Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection. Hepatol Res 2012; 42: 22-32.
28. Lok AS, Seeff LB, Morgan TR et al. HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-48.
29. Joko K, Goto T, Watanabe H et al. Effects of antiviral therapy for hepatitis C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group. Hepatol Res 2015 (Epub ahead of print).
30. Nkontchou G, Bastard JP, Ziol M et al. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol 2010; 53: 827-33.
31. Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: does it matter? J Hepatol 2012; 56 (Suppl 1): S56-65.